Segment Information

Second Quarter of the Fiscal Year Ending March 31, 2027

Sales composition ratio


Net sales
(Million yen)
Operating profit
(Million yen)
Operating profit
(%)
Parmaceutical Wholesale Business 291,058 1,523 0.52
Pharmacy Business 9,851 ▲55 -0.56
Veterinary Drug Wholesale Business 6,080 111 1.83
Pharmaceutical Business
(business of supporting introduction
 of unapproved drugs)
0 ▲856 ‐
Nursing Care-related Rental
and Other Business
2,816 ▲218 -7.74

Pharmaceutical Wholesale Business

In the pharmaceutical wholesale business, although there were negative impacts from the drug price revision, revenue increased due to efforts to focus on the sale of products eligible for the Patent-period price Maintenance Program for Innovative Drugs (PMP), mainly anticancer drugs, and influenza vaccines. On the profit side, segment profit decreased due to a decline in the gross profit margin resulting from intensifying market competition, rising purchase prices, and lower rebates, as well as an increase in selling, general and administrative expenses due to higher personnel costs and rising prices. Furthermore, expenses increased due to various upfront investments for the future, including DX promotion, and the strengthening of cybersecurity measures.
As a result of the above, net sales were 291,058 million yen (103.2% of the same period of the previous year), and segment profit (operating profit) was 1,523 million yen (73.2% of the same period of the previous year). 

Pharmacy Business

In the pharmacy business, although we worked to calculate dispensing fees through new store openings and the strengthening of family pharmacy functions, revenue decreased as we were unable to cover the impact of a decline in the number of prescriptions received due to the trend toward longer prescription durations. On the profit side, the segment recorded a loss due to an increase in costs resulting from higher personnel costs and rising prices. As a result of the above, net sales were 9,851 million yen (99.8% of the same period of the previous year), and segment loss (operating loss) was 55 million yen (segment profit of 135 million yen for the same period of the previous year).

 
 

 

Veterinary Drug Wholesale Business

In the Veterinary Drug Wholesale Business, revenue decreased as sales competition remained severe. On the profit side, profit increased as a result of efforts to manage delivery prices and costs. As a result of the above, net sales were 6,080 million yen (98.4% of the same period of the previous year), and segment profit (operating profit) was 111 million yen (103.1% of the same period of the previous year).

Pharmaceutical Business (business of supporting introduction of unapproved drugs)

The Pharmaceutical Business (business of supporting introduction of unapproved drugs) is a new business launched in September 2025, and no sales were posted in the six months ended September 30, 2026, while expenses necessary for business activities including research and development expenses came to 856 million yen, and segment loss amounted to the same amount of 856 million yen.

Nursing Care-related Rental and Other Business

In the Nursing Care-related Rental and Other Business, revenue increased due to factors including the consolidation of Yachiyo Care Holdings Co., Ltd. in December 2025. On the profit side, segment loss increased due to higher selling, general and administrative expenses resulting from rising personnel costs and inflation. As a result, net sales were 2,816 million yen (127.0% of the same period of the previous year), and segment loss (operating loss) was 218 million yen (segment loss of 122 million yen for the same period of the previous year).